Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.
about
Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccineStreptococcus pneumoniae carriage in the Gaza stripVirulence potential and genome-wide characterization of drug resistant Streptococcus pneumoniae clones selected in vivo by the 7-valent pneumococcal conjugate vaccineDirect effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children BrazilEffect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.Serotype replacement in disease after pneumococcal vaccinationPneumococcal transmission and disease in silico: a microsimulation model of the indirect effects of vaccination.Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Increasing incidence of Streptococcus pneumoniae serotype 19A and emergence of two vaccine escape recombinant ST695 strains in Liguria, Italy, 7 years after implementation of the 7-valent conjugated vaccine.Estimating the transmission dynamics of Streptococcus pneumoniae from strain prevalence data.Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy.Time is (still) of the essence: quantifying the impact of emergency meningitis vaccination response in Katsina State, Nigeria.Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine.Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations.Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal.Carried pneumococci in Massachusetts children: the contribution of clonal expansion and serotype switching.The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.Climate induces seasonality in pneumococcal transmissionPostvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complexA longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine eraComplex dynamics of synergistic coinfections on realistically clustered networks.Antibiotic resistance of Streptococcus pneumoniae, isolated from nasopharynx of preschool children with acute respiratory tract infection in Lithuania.Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis mediaCapsule Switching and Antimicrobial Resistance Acquired during Repeated Streptococcus pneumoniae Pneumonia Episodes.Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine.Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimesGeographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7Bacterial Density, Serotype Distribution and Antibiotic Resistance of Pneumococcal Strains from the Nasopharynx of Peruvian Children Before and After Pneumococcal Conjugate Vaccine 7.Influence of bacterial interactions on pneumococcal colonization of the nasopharynx.Invasive Pneumococcal Disease (IPD) Serotype Frequency in Iranian Patients.New frontiers in meningococcal vaccines.Use of the 13-valent pneumococcal conjugate vaccine in infants and young children.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.Impact of the antipneumococcal conjugate vaccine on the occurrence of infectious respiratory diseases and hospitalization rates in children.Nasopharyngeal carriage of Streptococcus pneumoniae in healthy Turkish children after the addition of PCV7 to the national vaccine schedule.Low rate of pneumococci non-susceptible to penicillin in healthy Swedish toddlers.The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination.
P2860
Q24629949-7A293B76-B317-4A9B-9A99-72C5281F9094Q28482482-3E25242E-8B51-45BD-A69F-1AAB018FD158Q28533656-F47B8478-2A13-4AFD-83D1-8D01D522D96EQ33706645-AA883857-0723-4DEA-83D5-CDB9433E27E8Q33869370-21CC4B82-3A64-43BF-9F46-79F11B7B366BQ34178363-2ED05C2C-DECE-4697-8263-CEDE4711BA08Q34606511-A6120478-65BE-4C94-8E29-984A3AFA7822Q34707962-52F1F5CC-4967-448B-A2F8-33A315C09A44Q34738766-C627D186-C6ED-4785-BDF7-3168592A5F39Q34791505-40C6663E-91B4-4361-B9E4-F81599F20760Q35016927-A3BB3A34-F5D5-4A07-932C-1EBB2A81C377Q35029246-553DDB67-DC82-49E0-8336-60EA9DE9FD72Q35055346-90AA8890-5123-4DEC-B41B-646150CFB2D9Q35091736-BA2B5BA8-D43D-471D-87B5-83048AF737F0Q35124898-B6998891-8901-4208-A449-AF9AC56943E8Q35139875-C45D1E64-B8D6-4361-A05C-4B97814F13AEQ35219958-E2BF230D-8746-472E-9727-FBAB74CD18D5Q35603351-635D8935-19CF-490B-B489-04041678A0ADQ35727870-06BBF5D8-D557-4AB6-97B8-510678462AD1Q35805223-19963ADB-6918-4FB5-AB86-EE007CD2DE50Q35887787-9084B98A-9EF7-48D5-BFF7-139D88F899E5Q35990026-69C0A363-6C2F-4D06-AA44-CB642BE6EEB0Q36024311-F8DF9E45-FCED-48CC-950D-FF26FB9C3B44Q36055346-17B54BF4-1378-447F-B3DB-039530F08D41Q36066860-BE5277F7-C423-41DE-8F15-7DEA8872C13DQ36079013-F1312844-BB8C-4585-93A6-D4112E9BCE02Q36174421-52E577D0-D8B5-4BCF-89E9-6B40744B9D8FQ36399999-1314DE19-769B-41BE-9071-90E7F4F2D753Q36763664-CC8F0831-A0E7-4AA7-8B86-4FCC5C4552A1Q37058954-D053F4CB-BAC1-4944-B6CD-F27E7B28D874Q37569208-8D0574A8-8E2D-4280-BD69-37014255C410Q37878480-037BDF25-EC21-441E-8201-B339DAAB8000Q37991405-46B13CC1-0B14-43B5-BD85-647C5B2658F2Q38082673-94D2294E-E023-4658-866B-B1F1A7184184Q38255287-329E2492-F2C0-4324-84C4-44DBECB1115AQ39657425-70F56DF6-8D6B-4063-8922-ADD4442843BBQ41346274-8A7F4A6E-2B51-4BAD-9852-20C7A67CB514Q42247332-76CAE3FB-5808-4083-A2C8-8B175635419CQ42288214-88D9DA55-6EBD-4C1B-8788-5C17D76819B8Q51157834-7E008095-91D9-4F19-A9C9-3E607B45FAAB
P2860
Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Impact of a pneumococcal conju ...... iage among children in Norway.
@ast
Impact of a pneumococcal conju ...... iage among children in Norway.
@en
type
label
Impact of a pneumococcal conju ...... iage among children in Norway.
@ast
Impact of a pneumococcal conju ...... iage among children in Norway.
@en
prefLabel
Impact of a pneumococcal conju ...... iage among children in Norway.
@ast
Impact of a pneumococcal conju ...... iage among children in Norway.
@en
P2093
P2860
P356
P1476
Impact of a pneumococcal conju ...... iage among children in Norway.
@en
P2093
Didrik F Vestrheim
Dominique A Caugant
E Arne Høiby
Ingeborg S Aaberge
P2860
P304
P356
10.1128/CVI.00435-09
P577
2010-01-27T00:00:00Z